Trump team is negotiating with weight-loss drug makers to lower prices to $149 a month: report
White House working to cut prices of Wegovy and Ozempic
- President Donald Trump is reportedly nearing deals with Eli Lilly and Novo Nordisk to offer discounted obesity drugs in exchange for Medicare coverage.
- Novo Nordisk's Wegovy could be offered for as little as $149 per month via TrumpRx, with Medicare covering it for weight loss purposes.
- Eli Lilly's Zepbound could be available for $299, also with Medicare coverage for weight loss, and the company could receive an FDA voucher for expedited review of a new weight-loss pill.
- These negotiations are part of Trump's ongoing efforts to lower prescription drug prices for people in the United States.
- Both Eli Lilly and Novo Nordisk have confirmed they are engaged in constructive discussions with the administration to expand patient access and promote affordability.